Aclaris Therapeutics (ACRS)

• Market cap: $373M
• 1 day: 5.2%
• 5 days: 14.67%
• 1 month: 49.57%
• 3 months: 74.62%
• 6 months: 119.11%
• Year to date: 38.71%
• 1 year: -2.82%
• 5 years: -12.47%
• 10 years: -84.4%
• Sector: Healthcare
• Industry: Biotechnology

About: Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Employees: 64